Contact Us

Product Pipeline
Senior Management
Board of Directors
Investor Relations
Careers
 
OGX-011
OGX-427
SN2310
CSP-9222
OGX-225
 

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

Our lead candidate, OGX-011, is being evaluated in five Phase 2 clinical trials, each of which has completed patient enrollment. Interim study results have previously been presented for each of the five clinical trials. In July 2008, we reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase 3 registration trial of OGX-011 via the Special Protocol Assessment (SPA) process.

 
Webcasts and Conferences

OncoGenex Conference Call to Discuss Partnering Plans for OGX-011
Dec 21, 2009, 8:30 AM ET

BioCentury NewsMakers
Sep 16, 2009, 2:30 PM ET

 

ASCO General Meeting Abstracts and Presentations for 2009


Webcast and Presentation
ASCO Webcast and Presentation for May 30, 2009

Product Pipeline

Click for more information on the OncoGenex product pipeline


[ DISCLAIMER ] [ PRIVACY STATEMENT ]
© 2004-2010 OncoGenex Pharmaceuticals Inc. All rights reserved.
Last Update: